相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Novel progesterone receptor modulators with gene selective and context-dependent partial agonism
Thomas J. Berrodin et al.
BIOCHEMICAL PHARMACOLOGY (2009)
LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms
Lars Verschuren et al.
JOURNAL OF LIPID RESEARCH (2009)
Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia
Adelheid Kratzer et al.
JOURNAL OF LIPID RESEARCH (2009)
Differential Biochemical and Cellular Actions of Premarin Estrogens: Distinct Pharmacology of Bazedoxifene-Conjugated Estrogens Combination
Thomas J. Berrodin et al.
MOLECULAR ENDOCRINOLOGY (2009)
Carboxylic acid based quinolines as liver X receptor modulators that have LXR beta receptor binding selectivity
Balhua Hu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Liver X Receptors (LXR) as Therapeutic Targets in Dyslipidemia
Jerzy Beltowski
CARDIOVASCULAR THERAPEUTICS (2008)
Recent advances in Liver X Receptor biology and chemistry
Bryan J. Goodwin et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2008)
Indazole-Based Liver X Receptor (LXR) Modulators with Maintained Atherosclerotic Lesion Reduction Activity but Diminished Stimulation of Hepatic Triglyceride Synthesis
Jay Wrobel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Antiatherosclerotic Effects of a Novel Synthetic Tissue-Selective Steroidal Liver X Receptor Agonist in Low-Density Lipoprotein Receptor-Deficient Mice
Dacheng Peng et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells
Elizabeth A. DiBlasio-Smith et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet-induced fatty liver
Xinqiang Huang et al.
DIABETES (2007)
Mouse models for atherosclerosis and pharmaceutical modifiers
Susanne Zadelaar et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE
Michelle N. Bradley et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man
T. Lundasen et al.
JOURNAL OF INTERNAL MEDICINE (2006)
Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis
Baihua Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice
M Van Eck et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo
LR Brunham et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Synthetic LXR agonists increase LDL in CETP species
PHE Groot et al.
JOURNAL OF LIPID RESEARCH (2005)
Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition
CA Argmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Regulation of complement C3 expression by the bile acid receptor FXR
JL Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Toll-like receptors, endocrine stress response, and arteriosclerosis
SR Bornstein et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Fibroblast growth factor 19 increases metabolic rate I and reverses dietary and leptlin-deficient diabetes
L Fu et al.
ENDOCRINOLOGY (2004)
Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor
EM Quinet et al.
JOURNAL OF LIPID RESEARCH (2004)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes - A randomized controlled trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
LXRs: new therapeutic targets in atherosclerosis?
SB Joseph et al.
CURRENT OPINION IN PHARMACOLOGY (2003)
T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice
N Terasaka et al.
FEBS LETTERS (2003)
Identification of macrophage liver X receptors as inhibitors of atherosclerosis
RK Tangirala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Synthetic LXR ligand inhibits the development of atherosclerosis in mice
SB Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors α and β
JJ Repa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity
E Tomlinson et al.
ENDOCRINOLOGY (2002)
Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues
M Van Eck et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Role of LXRs in control of lipogenesis
JR Schultz et al.
GENES & DEVELOPMENT (2000)
Identification of a chemical tool for the orphan nuclear receptor FXR
PR Maloney et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4
CD Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)